AstraZeneca PLC (AZN) is a publicly traded Healthcare sector company. As of October 1, 2026, AZN trades at $162.00 with a market cap of $254.67B and a P/E ratio of 0.00. AZN moved -1.67% today. Year to date, AZN is -11.83%; over the trailing twelve months it is +5.23%. Its 52-week range spans $122.48 to $212.71. Analyst consensus is strong buy with an average price target of $212.40. Rallies surfaces AZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AstraZeneca strikes clinical collaboration with Summit to test ADC sonesitatug vedotin with ivonescimab in GI cancers: AstraZeneca agreed to invest $2 billion in Summit Therapeutics through convertible preferred stock, with rights equivalent to about 12% of its outstanding common stock, or 10.6% on a fully diluted basis. The companies will share costs for clinical trials combining their medicines in gastrointestinal cancers while retaining their respective development and commercial rights.
| Metric | Value |
|---|---|
| Price | $162.00 |
| Market Cap | $254.67B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.80% |
| 52-Week High | $212.71 |
| 52-Week Low | $122.48 |
| Volume | 1.96M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
17 analysts cover AZN: 0 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $212.40.